# Bio-Gate AG Cuts 2026 Revenue Outlook Following Weak First Half

- URL: https://stocks.freetheai.org/news/bio-gate-ag-cuts-2026-revenue-outlook-following-weak-first-half-ce7c2c
- Published: 2026-10-09T13:55:03Z
- Category: earnings; sentiment: bearish; impact: medium
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Bio-Gate AG (BIG1) has lowered its full-year financial outlook for 2026 after reporting a decline in sales during the first half of the year. The medical technology firm generated revenue of 2.8 million euros in the first six months of 2026, representing an 18 percent drop compared to the same period in the previous year. Operating losses also widened, with earnings before interest, taxes, depreciation, and amortization (EBITDA) falling to negative 0.814 million euros from negative 0.723 million euros last year.

The downturn stems from reduced orders from two of the company's major customers, which has negatively affected its dermacosmetics and animal care segments. Due to these portfolio and timing challenges, the company now expects full-year 2026 revenue to fall between 6.0 million euros and 6.9 million euros, down from its previous forecast of 6.9 million euros to 7.9 million euros. Bio-Gate AG projects a full-year EBITDA loss of 0.9 million euros to 1.1 million euros, and an operating loss (EBIT) of 1.1 million euros to 1.5 million euros.

Going forward, the company's financial health will depend on its ability to secure a recovery in order volumes and complete key milestone deliveries. Investors will also be watching whether implemented cost-reduction measures can successfully translate into positive cash flow and mitigate ongoing cash burn risks.

## Key points

- Bio-Gate AG reported first-half 2026 revenue of 2.8 million euros, representing an 18 percent decline year-over-year.
- The company lowered its full-year 2026 revenue guidance to a range of 6.0 million to 6.9 million euros.
- First-half operating losses widened to negative 0.814 million euros compared to negative 0.723 million euros in the prior year period.
- The outlook cut was driven by lower orders from two key customers, affecting the animal care and dermacosmetics divisions.

## Questions and answers

### Why did Bio-Gate AG lower its 2026 revenue guidance?

Bio-Gate AG reduced its forecast due to a weaker first-half performance caused by timing and portfolio issues, alongside decreased order volumes from two of its major customers in the dermacosmetics and animal care sectors.

### What were Bio-Gate AG's financial results for the first half of 2026?

The company reported first-half revenue of 2.8 million euros, down about 18 percent year-over-year. Its EBITDA loss widened to 0.814 million euros, compared to a loss of 0.723 million euros in the same period last year.

### What is Bio-Gate AG's new financial outlook for full-year 2026?

The company now expects full-year revenue of 6.0 million to 6.9 million euros. It also projects an EBITDA loss of 0.9 million to 1.1 million euros and an operating loss (EBIT) between 1.1 million and 1.5 million euros.